RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling

Authorized Users Only
2011
Authors
Antić, Darko
Mihaljević, Biljana
Čokić, Vladan
Dencic-Fekete, Marija
Karan-Đurašević, Teodora
Pavlović, Sonja
Milić, Nataša
Elezović, Ivo
Article (Published version)
Metadata
Show full item record
Abstract
We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).
Keywords:
Lymphoma and Hodgkin disease / molecular genetics / prognostication
Source:
Leukemia & Lymphoma, 2011, 52, 7, 1394-1397
Publisher:
  • Taylor & Francis Ltd, Abingdon

DOI: 10.3109/10428194.2011.578311

ISSN: 1042-8194

PubMed: 21699385

WoS: 000291992400036

Scopus: 2-s2.0-79959613190
[ Google Scholar ]
5
5
URI
http://rimi.imi.bg.ac.rs/handle/123456789/336
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Antić, Darko
AU  - Mihaljević, Biljana
AU  - Čokić, Vladan
AU  - Dencic-Fekete, Marija
AU  - Karan-Đurašević, Teodora
AU  - Pavlović, Sonja
AU  - Milić, Nataša
AU  - Elezović, Ivo
PY  - 2011
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/336
AB  - We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).
PB  - Taylor & Francis Ltd, Abingdon
T2  - Leukemia & Lymphoma
T1  - Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling
EP  - 1397
IS  - 7
SP  - 1394
VL  - 52
DO  - 10.3109/10428194.2011.578311
UR  - conv_2524
ER  - 
@article{
author = "Antić, Darko and Mihaljević, Biljana and Čokić, Vladan and Dencic-Fekete, Marija and Karan-Đurašević, Teodora and Pavlović, Sonja and Milić, Nataša and Elezović, Ivo",
year = "2011",
abstract = "We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p  lt  0.0001).",
publisher = "Taylor & Francis Ltd, Abingdon",
journal = "Leukemia & Lymphoma",
title = "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling",
pages = "1397-1394",
number = "7",
volume = "52",
doi = "10.3109/10428194.2011.578311",
url = "conv_2524"
}
Antić, D., Mihaljević, B., Čokić, V., Dencic-Fekete, M., Karan-Đurašević, T., Pavlović, S., Milić, N.,& Elezović, I.. (2011). Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma
Taylor & Francis Ltd, Abingdon., 52(7), 1394-1397.
https://doi.org/10.3109/10428194.2011.578311
conv_2524
Antić D, Mihaljević B, Čokić V, Dencic-Fekete M, Karan-Đurašević T, Pavlović S, Milić N, Elezović I. Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling. in Leukemia & Lymphoma. 2011;52(7):1394-1397.
doi:10.3109/10428194.2011.578311
conv_2524 .
Antić, Darko, Mihaljević, Biljana, Čokić, Vladan, Dencic-Fekete, Marija, Karan-Đurašević, Teodora, Pavlović, Sonja, Milić, Nataša, Elezović, Ivo, "Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling" in Leukemia & Lymphoma, 52, no. 7 (2011):1394-1397,
https://doi.org/10.3109/10428194.2011.578311 .,
conv_2524 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB